feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouUnited StatesUnited States
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / New Drug Mimics Exercise to Burn Fat, Build Muscle

New Drug Mimics Exercise to Burn Fat, Build Muscle

10 Dec, 2025

•

Summary

  • New drug ATR-258 activates muscle pathways to burn fat and boost glucose uptake.
  • Unlike GLP-1s, it helps users lose weight while preserving muscle mass.
  • The oral medication is in early clinical trials, showing promise and good tolerance.
New Drug Mimics Exercise to Burn Fat, Build Muscle

Scientists have developed a novel oral medication, ATR-258, which demonstrates the potential to mimic the effects of exercise by promoting fat burning and enhancing muscle function. This new compound targets muscle pathways, supporting muscle mass preservation during weight loss, a significant concern with current popular weight-loss drugs like GLP-1 agonists.

Unlike injectable GLP-1s that primarily work on appetite regulation and can lead to muscle mass reduction, ATR-258 offers a distinct mechanism. Early preclinical and Phase 1 human trials suggest it improves blood sugar levels and supports muscle maintenance without excessive cardiac stimulation. The drug was found to be well-tolerated in study participants.

While ATR-258 is still in its early stages of clinical development, its ability to preserve muscle mass is particularly noteworthy. Maintaining muscle is vital for overall metabolic health, strength, and preventing issues like frailty. Further clinical trials are necessary before the medication can be considered for FDA approval and public use.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
ATR-258 is a beta-2 agonist in early trials that activates muscle pathways to burn fat and improve glucose uptake, aiming to preserve muscle mass.
ATR-258 is an oral drug that preserves muscle mass, unlike many injectable GLP-1s which can cause muscle loss alongside weight reduction.
ATR-258 is still in early clinical trials and requires further testing and FDA approval, so it will not be available for some time.

Read more news on

Healthside-arrow
trending

Ohio snow emergency declared

trending

Significant snow expected Sunday

trending

Warrington Hospital baby death

trending

TikTok down in United States

trending

London celebrates Chinese New Year

trending

Liza Minnelli defends AI use

trending

Duke Energy assists Carolinas

trending

New Dragon Ball Super anime

trending

Dončić leads Lakers over Mavericks

You may also like

Weight Loss Jabs Reshape Restaurant Menus

17 Jan • 28 reads

article image

New Drugs May Stop Muscle Loss During Weight Loss

19 Dec, 2025 • 115 reads

article image

Ozempic Launches in India: Diabetes & Weight Game-Changer?

12 Dec, 2025 • 192 reads

article image

Cats Get Their Own Weight-Loss Drug Implant

11 Dec, 2025 • 208 reads

Weight Drugs Cause Muscle Loss: Exercise is Key

9 Dec, 2025 • 194 reads

article image